Red Light Holland (TSE:TRIP) has released an update.
Red Light Holland Corp. has partnered with neuropsychopharmacology expert Professor David Nutt and Drug Science to conduct a groundbreaking study on psilocybin microdosing, revealing notable gender-specific usage patterns and therapeutic possibilities. The research, based on real-world data from the Netherlands, highlights potential benefits for conditions such as migraines, OCD, depression, PMS, and menopause. The company aims to use these findings to support global regulatory changes and improve access to psilocybin therapies.
For further insights into TSE:TRIP stock, check out TipRanks’ Stock Analysis page.
